Evidence map›Paper›PMID 38112978›Full record

ReviewMedical oncology (Northwood, London, England)2023

Understanding the charismatic potential of nanotechnology to treat skin carcinoma.

Aamravi Sathe, Bhupendra G Prajapati, Sankha Bhattacharya

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Aamravi SatheDepartment of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, 425405, India.
Bhupendra G PrajapatiShree S K Patel College of Pharmaceutical Education and Research, Ganpat University, Mahesana, Gujarat, 384012, India.
Sankha BhattacharyaDepartment of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, 425405, India. sankhabhatt@gmail.com.ORCID http://orcid.org/0000-0002-0771-9582
Narsee Monjee Institute of Management Studies · INGanpat University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoma is a condition that continues to pose a significant challenge, despite current medical advances. Skin carcinoma is the leading cause of cancer, and it has seen a massive increase all over the world. The challenges with current treatment are due to toxicity that leads to many more skin complications. Due to this to avoid such complications by designing diverse nanoparticles as delivery carriers, nanomedicine is employed as a hub for diagnostics and therapy. Liposomes, gold nanoparticles, transferases, nanofibers, etc., can all be used as delivery nanocarriers. These nanoparticles' structures and characteristics protect the medicine from degradation and improve its stability. Surface modifying agents and procedures are employed to functionalize nanoparticles, resulting in smart delivery systems. The application of nanotechnology-based approaches systematically increases drug delivery to target cells. Skin cancer has several challenges, including a long time to diagnose early types of cancer and a slower growth rate. This review focuses on innovative skin cancer therapy techniques, focusing on nanotechnology and the challenges associated with current treatment of skin cancer.

Indexed as

CarcinomaMetal NanoparticlesNanoparticlesSkin NeoplasmsDrug CarriersDrug Delivery SystemsGoldHumansNanotechnologyDrug CarriersGoldMelanomaMolecular mechanismNanotechnologyNon-melanomaUltraviolet radiation

Identifiers

PMID38112978
OpenAlexW4389936019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.